[EN] LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DIAMINES CYCLIQUES CONTENANT DU LACTAME ET LEURS DERIVES UTILISES EN TANT QU'INHIBITEURS DU FACTEUR XA
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2004082687A1
公开(公告)日:2004-09-30
The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trysin-like serine proteases, specifically factor Xa.
Efficient Synthesis of Dimeric Oxazoles, Piperidines and Tetrahydroisoquinolines from <i>N</i>
-Substituted 2-Oxazolones
作者:Yun He、Piyush K. Agarwal、I. N. Chaithanya Kiran、Ruocheng Yu、Bei Cao、Cheng Zou、Xinghua Zhou、Huacheng Xu、Biao Xu、Lei Zhu、Yu Lan、K. C. Nicolaou
DOI:10.1002/chem.201601471
日期:2016.6.1
practical method for the construction of heterocycles from N‐substituted 2‐oxazolonesthrough cascade, BF3⋅Et2O/H2O‐catalyzed reactions involving iminium ion generation and trapping by external or internal olefinic and aryl moieties is described. Mechanistic and computational studies revealed the strong protic acid HBF4 as the initiating catalyst for these cascade reactions. Providing access to novel molecular
为杂环的来自建筑的温和和实用的方法Ñ通过级联取代-2-恶唑酮,BF 3 ⋅Et 2 ø/ H 2涉及亚胺离子产生和由外部或内部烯属的和芳基部分捕获O形催化的反应进行说明。机理和计算研究表明,强质子酸HBF 4是这些级联反应的引发催化剂。这些过程提供了获得新颖分子多样性的途径,可以促进化学生物学研究,药物发现工作和天然产物合成。
LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
申请人:Qiao X Jennifer
公开号:US20070135428A1
公开(公告)日:2007-06-14
The present application describes lactam-containing cyclic diamines and derivatives thereof of Formula I:
P
4
-M-M
4
I
or pharmaceutically acceptable salt forms thereof, wherein M is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.